Publications in collaboration with researchers from Hospital Clinic Barcelona (57)

2024

  1. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection

  2. Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

    HemaSphere

  3. Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, Vol. 42, Núm. 1

  4. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, Vol. 137, pp. 98-110

  2. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    Blood Cancer Journal

  3. Genomic landscape of follicular lymphoma across a wide spectrum of clinical behaviors

    Hematological Oncology, Vol. 41, Núm. 4, pp. 631-643

  4. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  5. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

    Blood Advances, Vol. 6, Núm. 7, pp. 2427-2433

  3. Expression of p53 protein isoforms predicts survival in patients with multiple myeloma

    American Journal of Hematology, Vol. 97, Núm. 6, pp. 700-710

  4. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  5. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

  6. Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

    Blood Advances, Vol. 6, Núm. 18, pp. 5395-5402

  7. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

    Journal of Hematology and Oncology, Vol. 14, Núm. 1

  2. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  3. Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group

    British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530

2020

  1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050